ICU Medical Inc
NASDAQ:ICUI

Watchlist Manager
ICU Medical Inc Logo
ICU Medical Inc
NASDAQ:ICUI
Watchlist
Price: 143.77 USD 0.88% Market Closed
Market Cap: 3.5B USD

ICU Medical Inc
Investor Relations

ICU Medical Inc. emerged as an intriguing player in the healthcare sector, focusing on a mission-critical niche within the industry—safety and efficiency in medical devices for infusion therapy, oncology, and critical care applications. Founded with an innovative spirit, the company carved out a reputation by addressing a key challenge in the medical field: preventing bloodstream infections and the exposure of healthcare professionals to hazardous substances. This focus led to the development of specialized devices such as needle-free connectors and closed system transfer devices, which are integral to minimizing contamination risks. These innovations not only improved patient outcomes but also enhanced the working conditions of medical professionals, underpinning ICU Medical’s growth trajectory.

ICU Medical generates revenue by designing and manufacturing these life-saving devices, which are distributed across hospitals and healthcare facilities worldwide. The company's business model revolves around creating products that align with strict regulatory standards, ensuring both safety and superiority in healthcare settings. As they ventured into diverse product lines, such as infusion pumps and systems, the firm leveraged strategic acquisitions to expand market reach and technological capabilities. These initiatives underscored ICU Medical's commitment to operational synergy and product innovation, enabling the company to remain competitive and continue scaling its operations in a constantly evolving healthcare landscape. With a steady focus on both organic growth and strategic partnerships, ICU Medical remains a crucial player in the global health economy, dedicated to advancing patient care and the efficiency of healthcare delivery systems.

Show more
Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Last Earnings Call
Fiscal Period
Q3 2025
Call Date
Nov 6, 2025
AI Summary
Q3 2025

Revenue Growth: ICU Medical reported Q3 revenue of $533 million, with 5% organic growth but minus 8% reported year-over-year, impacted by the deconsolidation of IV Solutions.

Profitability: Gross margin rose to 41%, with adjusted EBITDA up 12% to $106 million and adjusted EPS up 28% to $2.03, helped by higher margins and lower operating expenses.

Guidance Raised: Full-year EBITDA guidance was increased to $395–$405 million (from $380–$390 million), and adjusted EPS outlook raised to $7.35–$7.65 (from $6.85–$7.15).

Segment Performance: Consumables and IV Systems delivered strong growth, with Consumables up 8% reported and IV Systems up 9% reported.

Cost Pressures: Tariffs remain a significant headwind, with Q3 tariff expense at $9 million and full-year tariff costs expected to reach $25 million.

Balance Sheet: Free cash flow improved, $273 million of debt repaid year-to-date, and recent refinancing expected to save $2 million annually in interest.

Innovation & Pipeline: Progress continues on product innovation and FDA approvals for new infusion hardware and software, supporting medium-term growth.

Portfolio Optimization: Management remains open to further portfolio adjustments, focusing on maximizing value and growth in core segments.

Key Financials
Revenue
$533 million
Gross Margin
41%
Adjusted EBITDA
$106 million
Adjusted EPS
$2.03
Free Cash Flow
$28 million
Debt Outstanding
$1.3 billion
Principal Debt Payments (YTD)
$273 million
Cash
$300 million
Tariff Expense (Q3)
$9 million
Consumables Revenue Growth
up 8% reported; 7% organic
IV Systems Revenue Growth
up 9% reported; 8% organic
Vital Care Revenue Growth
down 52% reported; down 4% organic
Adjusted SG&A Expense
$109 million
Adjusted R&D Expense
$21 million
Total Adjusted Operating Expenses
$130 million
Restructuring, Integration, and Strategic Expenses
$13 million
Net Interest Expense (Q3)
$20 million
Adjusted Effective Tax Rate
27%
Diluted Shares Outstanding
24.8 million
Earnings Call Recording
Other Earnings Calls

Management

Mr. Vivek Jain
CEO & Chairman of the Board
No Bio Available
Mr. Daniel Woolson
President
No Bio Available
Mr. Brian Michael Bonnell
CFO & Treasurer
No Bio Available

Contacts

Address
CALIFORNIA
San Clemente
951 Calle Amanecer
Contacts
+19493662183.0
www.icumed.com